Vaxxinity

VAXX · OTC

Share price · VAXX

$0.00-0.00 (-80.00%) 3M

no price since 17 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VAXX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 14 Aug 2026+25400.0%

    Nothing announced by VAXX that day or the session before.

  2. 2 Jul 2026+16650.0%

    Nothing announced by VAXX that day or the session before.

  3. 18 Jun 2026+14900.0%

    Nothing announced by VAXX that day or the session before.

  4. 15 Jun 2026+19900.0%

    Nothing announced by VAXX that day or the session before.

  5. 9 Jun 2026+7400.0%

    Nothing announced by VAXX that day or the session before.

  6. 27 Apr 2026+19900.0%
  7. 20 Apr 2026+9900.0%
  8. 1 Apr 2026+9900.0%

    Nothing announced by VAXX that day or the session before.

  9. 11 Mar 2026+9900.0%

    Nothing announced by VAXX that day or the session before.

  10. 4 Feb 2026+22150.0%

    Nothing announced by VAXX that day or the session before.

Share of unusual movement by asset

For each asset, the share of VAXX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—0%
Sessions with no dated event—100%

No dated announcements about its assets since 2 Jul 2024.

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
UB-311No recent activity
Phase 2
Amyloid-betaVaccine
Alzheimer's Disease
Early Alzheimer's Disease
Phase 1
alpha-synucleinVaccine
Parkinson's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (7)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-Q3—$7.9M$18M+ $25M short-term inv.$13M-$13M operating cash flowreport ↗

Vaxxinity reported R&D spend of $7.91M, down 36.6% YoY, cash and equivalents of $17.6M, and a net loss of $13.14M for Q3 2023.

Figures only: this period's report disclosed no narrative text

View 6 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-Q2—$8.3M$37M+ $19M short-term inv.$14M-$12M operating cash flowreport ↗
2023-Q1—$11M$23M+ $45M short-term inv.$18M-$20M operating cash flowreport ↗
2022-Q3—$12M$22M+ $80M short-term inv.$19M-$11M operating cash flowreport ↗
2022-Q2$0.1M$11M$114M$17M-$11M operating cash flowreport ↗
2022-Q1—$11M$125M$18M-$20M operating cash flowreport ↗
2021-Q3$0.1M$24M$89M$30M-$21M operating cash flowreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY—$36M$5.0M+ $25M short-term inv.$14M-$57M operating cash flowreport ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2022-FY$0$48M$35M+ $53M short-term inv.$19M-$56M operating cash flowreport ↗
2021-FY$0.1M$71M$145M+ $0 short-term inv.$34M-$81M operating cash flowreport ↗

Insider transactions

Insider-transaction reporting (SEC Form 4) applies to US-listed SEC filers. No SEC insider-filing record exists for this company's listing.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1 reporting institution held 0.0M shares ($43).

#InstitutionSharesValue
1NBC SECURITIES, INC.1,592$43